避孕药具市场规模、份额和成长分析（按类型、通路和地区划分）－2026-2033年产业预测

预计到 2024 年，避孕药具市场规模将达到 340.2289 亿美元，到 2025 年将达到 362.3438 亿美元，到 2033 年将达到 599.6775 亿美元，在预测期（2026-2033 年将达到 59.6775 亿美元，在预测期（2026-2033 年）年增长率为 6.5%。

避孕市场预计将受益于性行为感染发病率的上升以及越来越多的女性寻求避孕方法。在全球范围内，许多育龄女性都表达了对计划生育的需求，儘管目前已有数百万女性使用避孕方法，但仍存在未被满足的需求。旨在减少意外怀孕和提高人们对避孕选择认识的有针对性的计画预计将推动市场扩张。然而，人们对各种避孕方法可能产生的副作用（例如胃肠道问题、体重变化和情绪影响）的担忧可能会阻碍市场成长。此外，已开发地区不孕症的上升和性教育的不均衡也对市场发展构成挑战。

避孕药具市场驱动因素

全球贫困阶级和低收入群体中意外怀孕的发生率尤其高。造成这问题的主要原因是依赖无效的传统避孕方法，这会导致不安全堕胎和较高的孕产妇死亡率。在拉丁美洲等地区，年轻少女的孕产妇死亡风险显着高于年长女性。因此，推广避孕措施对于降低意外怀孕率、改善孕产妇健康以及为这些弱势群体提供更好的生育选择至关重要。

避孕药市场限制

由于长期服用口服避孕药会产生头痛、不规则出血和噁心等副作用，避孕药市场面临严峻的挑战。这些潜在的不良反应，尤其是在长期服用后，引发了消费者的担忧。此外，含有雌激素和黄体素的药物会增加血栓症形成的风险，进而导致心臟病发作等严重的健康併发症。因此，这些安全隐患导致消费者犹豫不决，可能阻碍避孕药在市场上的扩张和普及，并限制其整体成长潜力。

避孕药市场趋势

避孕市场正经历着向技术创新的重大转变，尤其是随着数位避孕的兴起。这种创新方法使用户能够透过线上平台监测月经週期并评估怀孕风险。由女性科技公司和其他机构开发的数位避孕解决方案利用预测演算法，帮助用户就其性健康做出明智的决定，从而改善预防策略并实现避孕方法的个人化。随着越来越多的消费者提高健康意识和科技素养，对数位解决方案的需求预计将会增长，这将改变避孕选择的格局，并提高生殖健康管理的可及性和用户参与度。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球避孕药具市场规模（按类型及复合年增长率划分）（2026-2033 年）

• 口服避孕药
• 复方口服避孕药
• 仅含黄体素的片剂
• 局部避孕药
• 避孕针
• 其他的

全球避孕药具市场规模（按分销类型和复合年增长率划分）（2026-2033 年）

• 医院和诊所
• 零售药房
• 网路药房
• 其他的

全球避孕药具市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2021-2023年营收年比比较

主要企业简介

• Pfizer Inc.（USA）
• Bayer AG（Germany）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Mylan NV（Netherlands）
• Novartis AG（Switzerland）
• Johnson & Johnson（USA）
• GlaxoSmithKline plc（UK）
• Allergan plc（Ireland）
• Agile Therapeutics, Inc.（USA）
• Piramal Healthcare（India）
• Organon & Co.（Netherlands）
• HRA Pharma（France）
• CooperSurgical, Inc.（USA）
• Church & Dwight Co., Inc.（USA）
• Merck & Co., Inc.（USA）
• Famy Care Ltd.（India）
• Sinopharm Group Co., Ltd.（China）
• Sun Pharmaceutical Industries Ltd.（India）
• Torrent Pharmaceuticals Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）

结论与建议

Contraceptive Drugs Market size was valued at USD 34022.89 Million in 2024 and is poised to grow from USD 36234.38 Million in 2025 to USD 59967.75 Million by 2033, growing at a CAGR of 6.5% during the forecast period (2026-2033).

The contraceptive drugs market is poised for growth driven by rising incidences of sexually transmitted diseases and a significant number of women desiring contraceptive solutions. A considerable global population of women of reproductive age expresses a need for family planning, with millions currently utilizing contraceptive methods while many others remain with unmet demand. Efforts to implement targeted programs aimed at reducing unplanned pregnancies and enhancing awareness around contraceptive options are anticipated to propel market expansion. Nevertheless, concerns regarding side effects such as gastrointestinal issues, weight changes, and emotional effects related to various contraceptive methods may hinder growth. Additionally, the increasing rates of infertility and inconsistent sex education in developed regions pose challenges to the market's advancement.

Top-down and bottom-up approaches were used to estimate and validate the size of the Contraceptive Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Contraceptive Drugs Market Segments Analysis

Global Contraceptive Drugs Market is segmented by type, distribution and region. Based on type, the market is segmented into oral contraceptives, combined oral contraceptive pills, progestogen-only pills, topical contraceptives, contraceptive injectable and others. Based on distribution, the market is segmented into hospital & clinics, retail pharmacy, online pharmacy and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Contraceptive Drugs Market

The prevalence of unintended pregnancies is notably high among poorer and low-income populations globally. A major contributor to this issue is the reliance on traditional contraceptive methods, which are often less effective. This scenario leads to a troubling incidence of unsafe abortions and maternal mortality. In regions such as Latin America, young teenagers face a significantly elevated risk of maternal death compared to older women. Consequently, the adoption of contraceptive drugs plays a vital role in reducing the rates of unplanned pregnancies, thereby improving maternal health outcomes and ensuring better reproductive choices for individuals in these vulnerable groups.

Restraints in the Contraceptive Drugs Market

The contraceptive drugs market faces significant challenges due to the side effects associated with prolonged use of birth control pills, which can include headaches, abnormal bleeding, and nausea. These potential adverse effects, particularly after extended use, raise concerns among consumers. Additionally, medications that contain estrogen and progesterone carry an increased risk of developing blood clots, which can result in serious health complications such as heart attacks. Consequently, these safety concerns contribute to consumer hesitance and may impede the expansion and acceptance of contraceptive pharmaceuticals in the market, limiting its overall growth potential.

Market Trends of the Contraceptive Drugs Market

The contraceptive drugs market is witnessing a significant shift towards technological advancements, particularly with the rise of digital contraception. This innovative approach allows individuals to monitor their menstrual cycles and assess pregnancy risk through online platforms. By leveraging predictive algorithms, digital contraceptive solutions, such as those developed by femtech companies, enable users to make informed decisions about their sexual health, improving prevention strategies and personalizing contraceptive methods. As more consumers become health-conscious and tech-savvy, the demand for digital solutions is anticipated to grow, reshaping the landscape of contraceptive options and enhancing accessibility and user engagement in reproductive health management.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Contraceptive Drugs Market Size by Type & CAGR (2026-2033)

• Market Overview
• Oral Contraceptives
• Combined Oral Contraceptive Pills
• Progestogen-Only Pills
• Topical Contraceptives
• Contraceptive Injectable
• Others

Global Contraceptive Drugs Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital & Clinics
• Retail Pharmacy
• Online Pharmacy
• Others

Global Contraceptive Drugs Market Size & CAGR (2026-2033)

• North America (Type, Distribution)
  • USA
  • Canada
• Europe (Type, Distribution)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Distribution)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Distribution)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Distribution)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agile Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Healthcare (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organon & Co. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HRA Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CooperSurgical, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Church & Dwight Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Famy Care Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinopharm Group Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations